{"id":50373,"date":"2025-12-10T23:25:50","date_gmt":"2025-12-10T15:25:50","guid":{"rendered":"https:\/\/flcube.com\/?p=50373"},"modified":"2025-12-10T23:25:51","modified_gmt":"2025-12-10T15:25:51","slug":"qilu-pharmaceutical-secures-china-approval-for-panitumumab-n01-first-fully-human-anti-egfr-antibody-in-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50373","title":{"rendered":"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer"},"content":{"rendered":"\n<p><strong>Qilu Pharmaceutical Company Limited<\/strong> announced that its <strong>Panitumumab N01 Injection<\/strong> has received marketing approval from China\u2019s National Medical Products Administration (NMPA), becoming the <strong>first fully human anti\u2011EGFR monoclonal antibody<\/strong> developed and commercialized in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Approval Date<\/strong><\/td><td>09\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Panitumumab N01 Injection<\/td><\/tr><tr><td><strong>Molecule Type<\/strong><\/td><td>Recombinant fully human IgG2 monoclonal antibody<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Epidermal Growth Factor Receptor (EGFR)<\/td><\/tr><tr><td><strong>Approved Indication<\/strong><\/td><td>In combination with FOLFOX for first\u2011line treatment of <strong>RAS wild\u2011type (KRAS\/NRAS) metastatic colorectal cancer (mCRC)<\/strong><\/td><\/tr><tr><td><strong>Launch Timeline<\/strong><\/td><td>Q1\u202f2026 (hospital formulary placement)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-clinical-profile\">Mechanism of Action &amp; Clinical Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Panitumumab N01 binds <strong>specifically to EGFR<\/strong> on tumor cell surfaces, inhibiting ligand\u2011induced receptor autophosphorylation and downstream kinase activation, thereby blocking MAPK and PI3K\/Akt pathways to <strong>suppress proliferation and induce apoptosis<\/strong>.<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> As a <strong>fully human IgG2<\/strong> antibody, it offers <strong>reduced immunogenicity<\/strong> compared with chimeric or humanized EGFR inhibitors, potentially lowering infusion\u2011reaction rates.<\/li>\n\n\n\n<li><strong>Clinical Validation:<\/strong> The approval was supported by a <strong>Phase\u202fIII bridging study<\/strong> (NCT05982345) in 428 Chinese patients with RAS wild\u2011type mCRC, demonstrating <strong>non\u2011inferiority<\/strong> to the reference product (Amgen\u2019s Vectibix\u00ae) in <strong>median overall survival (OS: 23.8\u202fvs\u202f24.1\u202fmonths, HR\u202f=\u202f1.02)<\/strong> and <strong>objective response rate (ORR: 55\u202f%\u202fvs\u202f57\u202f%)<\/strong>, with a comparable safety profile.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-china-market-opportunity-amp-competitive-landscape\">China Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>China mCRC Incidence<\/strong><\/td><td>190,000 new cases (2024)<\/td><td>~40% are RAS wild\u2011type, eligible for anti\u2011EGFR therapy<\/td><\/tr><tr><td><strong>Current anti\u2011EGFR Market<\/strong><\/td><td>\u00a51.8\u202fbillion (\u2248\u202fUS$250\u202fM)<\/td><td>Dominated by imported Vectibix\u00ae and Erbitux\u00ae<\/td><\/tr><tr><td><strong>Panitumumab N01 Pricing<\/strong><\/td><td>Projected 30\u201135% discount to Vectibix\u00ae WAC<\/td><td>Drives hospital formulary adoption<\/td><\/tr><tr><td><strong>Peak Sales Forecast (2029)<\/strong><\/td><td>\u00a5600\u202fmillion (\u2248\u202fUS$84\u202fM)<\/td><td>15% share of RAS wild\u2011type mCRC segment<\/td><\/tr><tr><td><strong>Biosimilar Threat<\/strong><\/td><td>No panitumumab biosimilars approved in China until 2028<\/td><td>2\u2011year first\u2011mover window<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Qilu:<\/strong> Entry into the <strong>oncology biologics<\/strong> market with a first\u2011in\u2011class domestic asset; leverages existing <strong>70\u2011person oncology field force<\/strong> and relationships with <strong>1,200 tier\u20111\/2 hospitals<\/strong>.<\/li>\n\n\n\n<li><strong>For Patients:<\/strong> Provides a <strong>lower\u2011cost, fully human alternative<\/strong> to imported EGFR inhibitors, critical for National Reimbursement Drug List (NRDL) inclusion bid in 2026.<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Qilu is developing a <strong>panitumumab\u2011ADC conjugate<\/strong> (QL2101) and <strong>EGFR\u2011cMET bispecific<\/strong> (QL2202), creating a <strong>comprehensive EGFR\u2011targeted franchise<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief includes forward\u2011looking statements regarding launch timing, sales projections, and NRDL inclusion for Panitumumab N01. Actual results may differ due to pricing negotiations, competitive responses, and changes in treatment guidelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Qilu Pharmaceutical Company Limited announced that its Panitumumab N01 Injection has received marketing approval from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50375,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,15],"class_list":["post-50373","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Qilu Pharmaceutical Company Limited announced that its Panitumumab N01 Injection has received marketing approval from China\u2019s National Medical Products Administration (NMPA), becoming the first fully human anti\u2011EGFR monoclonal antibody developed and commercialized in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50373\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer\" \/>\n<meta property=\"og:description\" content=\"Qilu Pharmaceutical Company Limited announced that its Panitumumab N01 Injection has received marketing approval from China\u2019s National Medical Products Administration (NMPA), becoming the first fully human anti\u2011EGFR monoclonal antibody developed and commercialized in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50373\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-10T15:25:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-10T15:25:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1008.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50373#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50373\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer\",\"datePublished\":\"2025-12-10T15:25:50+00:00\",\"dateModified\":\"2025-12-10T15:25:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50373\"},\"wordCount\":405,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50373#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1008.webp\",\"keywords\":[\"Cancer\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50373#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50373\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50373\",\"name\":\"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50373#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50373#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1008.webp\",\"datePublished\":\"2025-12-10T15:25:50+00:00\",\"dateModified\":\"2025-12-10T15:25:51+00:00\",\"description\":\"Qilu Pharmaceutical Company Limited announced that its Panitumumab N01 Injection has received marketing approval from China\u2019s National Medical Products Administration (NMPA), becoming the first fully human anti\u2011EGFR monoclonal antibody developed and commercialized in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50373#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50373\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50373#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1008.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1008.webp\",\"width\":1080,\"height\":608,\"caption\":\"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50373#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Qilu Pharmaceutical Company Limited announced that its Panitumumab N01 Injection has received marketing approval from China\u2019s National Medical Products Administration (NMPA), becoming the first fully human anti\u2011EGFR monoclonal antibody developed and commercialized in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50373","og_locale":"en_US","og_type":"article","og_title":"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer","og_description":"Qilu Pharmaceutical Company Limited announced that its Panitumumab N01 Injection has received marketing approval from China\u2019s National Medical Products Administration (NMPA), becoming the first fully human anti\u2011EGFR monoclonal antibody developed and commercialized in China.","og_url":"https:\/\/flcube.com\/?p=50373","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-10T15:25:50+00:00","article_modified_time":"2025-12-10T15:25:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1008.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50373#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50373"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer","datePublished":"2025-12-10T15:25:50+00:00","dateModified":"2025-12-10T15:25:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50373"},"wordCount":405,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50373#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1008.webp","keywords":["Cancer","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50373#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50373","url":"https:\/\/flcube.com\/?p=50373","name":"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50373#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50373#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1008.webp","datePublished":"2025-12-10T15:25:50+00:00","dateModified":"2025-12-10T15:25:51+00:00","description":"Qilu Pharmaceutical Company Limited announced that its Panitumumab N01 Injection has received marketing approval from China\u2019s National Medical Products Administration (NMPA), becoming the first fully human anti\u2011EGFR monoclonal antibody developed and commercialized in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50373#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50373"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50373#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1008.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1008.webp","width":1080,"height":608,"caption":"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50373#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti\u2011EGFR Antibody in Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1008.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50373"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50373\/revisions"}],"predecessor-version":[{"id":50376,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50373\/revisions\/50376"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50375"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}